Trial Overview
On August 5, 2026, the U.S. Department of Veterans Affairs announced the launch of PIVOT (Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression) — a multi-site, randomized, double-blind clinical trial evaluating psilocybin-assisted therapy for veterans with treatment-resistant depression (TRD), including those with concurrent PTSD.
The trial is conducted in collaboration with Compass Pathways using their proprietary COMP360 synthetic psilocybin formulation, which has already demonstrated positive 26-week durability data in the Phase 3 COMP006 trial.
Why This Matters
This is the first time the VA — the largest integrated healthcare system in the United States — has initiated a multi-site psilocybin trial. The VA healthcare system serves over 9 million veterans, many of whom suffer from treatment-resistant forms of depression and PTSD that have not responded to conventional pharmacotherapy or psychotherapy.
A recent pilot trial published in Communications Medicine (July 30, 2026) found that psilocybin-assisted therapy produced 75% remission rates in 12 veterans with severe, treatment-resistant PTSD at one month post-treatment, with no serious adverse events.
Regulatory Context
The PIVOT trial follows several major federal actions in 2026:
- April 18, 2026: Presidential executive order signed to accelerate medical treatments for serious mental illness, directing the FDA to fast-track psychedelic therapies with Breakthrough Therapy designations
- July 14, 2026: FDA finalized its first formal guidance for clinical investigations of psychedelic drugs
- September 14, 2026 (upcoming): FDA public hearing on the potential future therapeutic use of psychedelic drugs
Trial Details
| Parameter | Detail |
|---|---|
| Sponsor | U.S. Department of Veterans Affairs + Compass Pathways |
| Compound | COMP360 (synthetic psilocybin) |
| Design | Multi-site, randomized, double-blind, placebo-controlled |
| Population | Veterans with treatment-resistant depression ± PTSD |
| Primary Outcome | Change in depression severity (MADRS) |
| Status | Recruiting |
Body Mind State Assessment
The PIVOT trial represents the most significant institutional endorsement of psilocybin therapy to date. Combined with the FDA guidance finalization and the upcoming public hearing, the regulatory trajectory for psilocybin approval is now measurably accelerating. Compass Pathways is targeting a potential FDA approval decision in late 2026 or early 2027.
